Regulatory Alignment for Cancer Drug
OS Therapies Secures Regulatory Alignment in UK and EU for Cancer Drug Filing
Anonymous
OS Therapies, a gene-edited cancer immunotherapy company, has won regulatory approval to move forward with its treatment for osteosarcoma. Paris Star Online reports the UK's MHRA and EU's EMA agreed the company can use historical patient data in its application — a key milestone that clears the path for filing a Conditional Marketing Authorisation Application in the coming weeks.
The biotech firm plans to file applications in the UK, EU, and Australia for OSTHER2, its Listeria-based therapy targeting metastatic osteosarcoma. A confirmatory Phase 3 trial will begin in late 2026. The company is also pursuing accelerated approval in the US under the FDA's expedited review process.
Historical Data Gets Regulatory Green Light
Regulators approved OS Therapies' plan to use historical control data — information from past patient cases — instead of requiring a traditional control group. The Sudbury Star explains this approach is appropriate for the orphan indication, a rare disease with few patients. This decision shortens the timeline to market significantly.
The drug targets fully resected pulmonary metastatic osteosarcoma, a bone cancer where tumors have spread to the lungs but were surgically removed. Using historical comparisons allows faster approval for this small patient population without compromising safety standards.
Confirmatory Trial Starts in Fourth Quarter 2026
OS Therapies achieved full alignment with regulators on its Phase 3 trial design. Hanna Herald reports the company will begin this confirmatory study in Q4 2026. The trial will validate OSTHER2's safety and effectiveness in a larger patient population before full approval.
Conditional approvals allow earlier patient access while companies gather additional evidence. This accelerated pathway is common for therapies treating serious cancers with limited treatment options.
Multi-Region Regulatory Strategy Underway
OS Therapies is pursuing a parallel approval strategy across multiple markets. Chatham Daily News confirms the company is filing for Conditional Marketing Authorisation in the UK and EU simultaneously, alongside a separate application in Australia. A Biologics License Application under the FDA's Accelerated Approval program is also in progress for the US market.
Gene-edited Listeria-based therapies are a novel approach to cancer treatment. This technology uses modified bacteria to trigger immune responses against tumor cells, offering a distinct mechanism from traditional chemotherapy.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
11
Articles
11
Reach
11
Topics
A
AnonymousAuthor
